AMAG is clearly interested in going it alone. As this afternoon's announcement of a shareholder rights indicates, they are going to make it more difficult for any large interest to acquire the shares, cheaply.
interesting. Could read several things into this. As you say, could just be sending a message that they want to go it alone. Could also be they've gotten some indications or approaches on a takeover already, and the price isn't near to thier liking. (I'm just guessing).... but still interesting. Maybe we'll see a hostile attempt prior to the record date of the 17thh.. That would certainly bring some excitement to the stock.... Enjoy your Labor Day weekend.
The poison pill is common in many public companies, but Im thinking (speculating) that it is much less common in the biotech arena, where acquisitions by big-pharma is so prevalent.
This seems, to me, to be an outlier action by a small pharma. It most certainly suggests that management is confident in their business prospects, and that they neither need, nor desire the deep pockets of big-pharma
Of course, non of this negates their interest to co-partner with other entities for non-US marketing of Feraheme.